Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML

- Hassan, Nunki, Yi, Hangyu, Carter, Daniel R., Cheung, Belamy B., Norris, Murray, Haber, Michelle, Kavallaris, Maria, Marshall, Glenn M., Zhang, Xu Dong, Liu, Tao, Wang, Jianlong, Liebermann, Dan A., Malik, Bilal, D'Andrea, RJ, Wang, JY, Gaspard-Boulinc, Lucie, Samaraweera, Saumya E., Casolari, Debora A., Seneviratne, Janith, Balachandran, Anushree, Chew, Tracy, Duly, Alastair

Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies

- Germon, Zacary P., Sillar, Jonathan R., McLachlan, Tabitha, Schjenken, John E., Skerrett-Byrne, David A., Huang, Honggang, Melo-Braga, Marcella N., Plank, Maximillan W., Alvaro, Frank, Chamberlain, Janis, De Iuliis, Geoff, Aitken, R. John, Mannan, Abdul, Nixon, Brett, Wei, AH, Enjeti, Anoop K., Huang, Y, Lock, RB, Larsen, MR, Lee, Heather, Vaghjiani, V, Cain, JE, de Bock, CE, Duchatel, Ryan J., Verrills, Nicole M., Dun, Matthew D., Staudt, Dilana, Murray, Heather C., Findlay, Izac J., Jackson, Evangeline R., McEwen, Holly P., Douglas, Alicia M.

Molecular and phosphoproteomic characterisation of FLT3 inhibitor resistance in acute myeloid leukaemia

- Staudt Barreto, Dilana Elisabeth

Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection

- Staudt, Dilana E., Murray, Heather C., Findlay, Izac J., Kearney, Padraic S., Mannan, Abdul, McEwen, Holly P., Douglas, Alicia M., Nixon, Brett, Verrills, Nicole M., Dun, Matthew D., Skerrett-Byrne, David A., Smith, Nathan D., Jamaluddin, M. Fairuz B., Kahl, Richard G. S., Duchatel, Ryan J., Germon, Zacary P., McLachlan, Tabitha, Jackson, Evangeline R.

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

- Staudt, Dilana, Murray, Heather C., McLachlan, Tabitha, Alvaro, Frank, Enjeti, Anoop K., Verrills, Nicole M., Dun, Matthew D.

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT⁺ cancers

- Roberts, Kathryn G., Smith, Amanda M., Sim, Alistair T. R., Ashman, Leonie K., Verrills, Nicole M., McDougall, Fiona, Carpenter, Helen, Horan, Martin, Neviani, Paolo, Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Perrotti, Danilo